Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 1, 2002, Pages 35-50

  Umland, Shelby P ^a   Schleimer, Robert P ^b   Johnston, Sebastian L ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Asthma; Glucocorticoids; Mechanisms; Mometasone furoate; Transcription

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CELL ADHESION MOLECULE; CHEMOKINE; DEXAMETHASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; I KAPPA B; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 3; INTERLEUKIN 5; MOMETASONE FUROATE; PREDNISONE; TRANSCRIPTION FACTOR; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BINDING SITE; DNA BINDING; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; MEDIATOR RELEASE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SIDE EFFECT; TRANSCRIPTION INITIATION; WILD TYPE;

EID: 0036352690     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2001.0312     Document Type: Article

References (169)

1. Efficacy and safety of inhaled corticosteroids. New developments
2. Structure-activity relationships of a series of novel topical corticosteroids
3. Mometasone furoate. A review of its intranasal use in allergic rhinitis
4. Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler
5. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
6. Bioavailability and metabolism of mometasone furoate following administration by metered dose and dry powder inhalers in healthy human volunteers
7. Molecular basis of allergic diseases
8. Inflammation in asthma: The cornerstone of the disease and target of therapy
9. Guidelines for the diagnosis and management of asthma, 1997
10. A comparison of the efficacy and safety of inhaled corticosteroids in asthma
11. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids
12. The British guidelines on asthma management 1995 review and position statement
13. Establishing a therapeutic index for the inhaled corticosteroids: Part II. Comparisons of systemic activity and safety among different inhaled corticosteroids
14. Attained adult height after childhood asthma: Effect of glucocorticoid therapy
15. Influence of inhaled corticosteroids on growth: A pediatric endocrinologist's perspective
16. Effect of asthma and its treatment on growth: Four year follow up of cohort of children from general practices in Tayside, Scotland
17. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids
18. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home
19. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children
20. The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis
21. Respiratory viruses and exacerbations of asthma in adults
22. Studies of the community and family: Acute respiratory illness and infection
23. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: Randomised double blind placebo controlled trial
24. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription
25. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
26. Molecular mechanisms of steroid action in asthma
27. Glucocorticoids: Mechanisms of action and anti-inflammatory potential in asthma
28. Glucocorticoid receptors and actions
29. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action
30. Adrenocorticotropic hormone: Adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones
31. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta
32. Glucocorticoid mechanism of action: Monoclonal antibodies as experimental tools
33. A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptor
34. Disruption of the glucocorticoid receptor assembly with heat shock protein 90 by a peptidic antiglucocorticoid
35. A conserved proline in the hsp90 binding region of the glucocorticoid receptor is required for hsp90 heterocomplex stabilization and receptor signaling
36. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha- acetal-substituted glucocorticoids
37. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model
38. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids
39. Comparison of inhaled corticosteroids
40. The glucocorticoid receptor
41. The genomic structure of the human glucocorticoid receptor
42. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1
43. Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone
44. Identification of a glucocorticoid response element in the rat beta2-adrenergic receptor gene
45. Phenylethanolamine N-methyltransferase gene expression: Synergistic activation by egr-1, AP-2 and the glucocorticoid receptor
46. Hormone-mediated repression: A negative glucocorticoid response element from the bovine prolactin gene
47. Glucocorticoid repression of pro-opiomelanocortin gene transcription
48. Molecular mechanisms of glucocorticoid inhibition of human proopiomelanocortin gene transcription
49. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene
50. The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression
51. Glucocorticoids repress transcription from a negative glucocorticoid response element recognized by two homeodomain-containing proteins, Pbx and Oct-1
52. The coregulator exchange in transcriptional functions of nuclear receptors
53. Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300
54. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor
55. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone
56. Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction
57. The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung
58. Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells
59. Effects of dexamethasone on cytokine and phorbol ester stimulated c-Fos and c-Jun DNA binding and gene expression in human lung
60. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor
61. Negative cross-talk between RelA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids
62. DNA binding of the glucocorticoid receptor is not essential for survival
63. Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids
64. Effect of beta-agonists on inflammatory cells
65. Interference of pathway specific transcription factors
66. Nuclear receptor/AP-1 interaction
67. Transrepression of c-jun gene expression by the glucocorticoid receptor requires both AP-1 sites in the c-jun promoter
68. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids
69. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis
70. DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells
71. Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells
72. Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil transendothelial migration by eosinophil-active cytokines
73. Cytokine regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production by human retinal pigment epithelial cells
74. Glucocorticoid regulation of GM-CSF: Evidence for transcriptional mechanisms in airway epithelial cells
75. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma
76. Regulation of the action of hydrocortisone in airway epithelial cells by 11beta-hydroxysteroid dehydrogenase
77. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation
78. Role of cAMP response element binding protein (CBP) in mometasone-induced gene repression
79. Mechanisms of glucocorticoid function in human leukemic cells: Analysis of receptor gene mutants of the activation-labile type using the covalent affinity ligand dexamethasone mesylate
80. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts
81. The AU-rich sequences in the 3′ untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids
82. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA
83. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Post-transcriptional mechanisms
84. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation
85. Regulation of interleukin-1 beta production by glucocorticoids in human monocytes: The mechanism of action depends on the activation signal
86. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: Mediation by decreased mRNA stability
87. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different post-transcriptional mechanisms
88. Interleukin-1 and its biologically related cytokines
89. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme
90. Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium
91. Adhesion of human basophils, eosinophils, and neutrophils to interleukin-1-activated human vascular endothelial cells: Contributions of endothelial cell adhesion molecules
92. Interleukin-1
93. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4
94. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment
95. Regulation of inhibitory pathways of the interleukin-1 system
96. Glucocorticosteroids: Their mechanism of action and use in allergic diseases
97. The type II 'receptor' as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand properties of the released decoy receptor
98. Regulation of bovine interleukin-1 receptors
99. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF
100. Interleukin-5 production by human airway epithelial cells
101. The mechanism of IL-5 signal transduction
102. Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes
103. Inhibition of interleukin-5 gene expression by dexamethasone
104. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression
105. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids
106. IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils
107. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1
108. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells
109. Interleukin-13: Central mediator of allergic asthma
110. Anti-interleukin-4 inhibits immunoglobulin E production in a murine model of atopic asthma
111. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice
112. Requirement for IL-13 independently of IL-4 in experimental asthma
113. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis
114. Dysregulation of interleukin-4, interleukin-5, and interferon-gamma gene expression in steroid-resistant asthma
115. Cytokines in symptomatic asthma airways
116. Asthma, viruses, and nitric oxide
117. Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: Differential sensitivity of GM-CSF, IL-1 beta, and IL-6
118. Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation
119. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis
120. Induction of interleukin 6 by ionizing radiation in a human epithelial cell line: Control by corticosteroids
121. Interleukin-6 production in human fibroblasts derived from periodontal tissues is differentially regulated by cytokines and a glucocorticoid
122. TNF alpha mRNA expression in allergic inflammation
123. Production of granulocyte/macrophage colony-stimulating factor in human airways during allergen-induced late-phase reactions in atopic subjects
124. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte-macrophage colony-stimulating factor by in situ hybridization
125. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor
126. Cytokine inhibition by a novel steroid, mometasone furoate
127. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells
128. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines
129. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice
130. Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids
131. RANTES, macrophage-inhibitory protein 1alpha, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children
132. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo
133. Nitric oxide and bronchial hyperresponsiveness
134. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: Effect of inhaled glucocorticoid
135. Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells
136. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B
137. Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells
138. Nuclear factor-kappa B
139. Nuclear factor kappa B: A pivotal role in the systemic inflammatory response syndrome and new target for therapy
140. Nuclear factor kappa B: Important transcription factor and therapeutic target
141. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
142. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
143. Identification of a specific interleukin-1 inhibitor in the urine of febrile patients
144. A urine inhibitor of interleukin-1 activity affects both interleukin-1 alpha and 1 beta but not tumour necrosis factor-alpha
145. Corticosteroids induce intracellular interleukin-1 receptor antagonist type I expression by a human airway epithelial cell line
146. Interleukin-10 and its receptor
147. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy
148. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes
149. Inflammation and cell-cell interactions in airway hyperresponsiveness
150. Phenotyping and cytokine regulation of the BEAS-2B human bronchial epithelial cell: Demonstration of inducible expression of the adhesion molecules VCAM-1 and ICAM-1
151. Fluticasone propionate - An update on preclinical and clinical experience
152. The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules
153. The anti-inflammatory profile of fluticasone propionate
154. Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines
155. Effect of dexamethasone on intercellular adhesion molecule-1 expression on cultured bronchial epithelial cells stimulated by inflammatory cytokines
156. Inhibition of lymphocyte adhesion to cytokine-activated synovial fibroblasts by glucocorticoids involves the attenuation of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 gene expression
157. Effect of dexamethasone, 6-mercaptopurine and cyclosporine A on intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression
158. Regulation of ICAM-1 by dexamethasone in a human vascular endothelial cell line EAhy926
159. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies
160. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena
161. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge
162. Expression of endothelial and leukocyte adhesion molecules intercellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma
163. Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells
164. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes
165. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity
166. An in vitro comparison of commonly used topical glucocorticoid preparations
167. Glucocorticosteroids inhibit leukotriene production